このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Getinge 将来の成長

Future 基準チェック /26

Getingeは、10.7%と4.4%でそれぞれ年率10.7%で利益と収益が成長すると予測される一方、EPSはgrowで10.5%年率。

主要情報

10.7%

収益成長率

10.5%

EPS成長率

Medical Equipment 収益成長	0%
収益成長率	4.4%
将来の株主資本利益率	n/a
アナリストカバレッジ	Good
最終更新日	05 Jun 2023

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

BMV:GETIB N - アナリストの将来予測と過去の財務データ ( )SEK Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2025	33,343	3,892	4,456	5,501	9
12/31/2024	31,721	3,480	3,746	5,017	9
12/31/2023	30,150	2,987	2,798	4,418	10
3/31/2023	29,251	2,543	1,105	2,293	N/A
12/31/2022	28,292	2,491	2,231	3,367	N/A
9/30/2022	27,781	2,707	2,835	3,916	N/A
6/30/2022	27,146	2,665	3,085	4,135	N/A
3/31/2022	27,062	2,860	4,188	5,173	N/A
12/31/2021	27,049	2,970	5,630	6,560	N/A
9/30/2021	27,900	3,292	6,585	7,533	N/A
6/30/2021	29,571	3,916	6,893	7,811	N/A
3/31/2021	29,955	3,612	7,021	7,988	N/A
12/31/2020	29,819	3,239	6,154	7,199	N/A
9/30/2020	29,478	3,050	5,218	6,336	N/A
6/30/2020	27,738	1,878	4,239	5,437	N/A
3/31/2020	27,044	1,487	3,461	4,690	N/A
12/31/2019	26,559	1,222	2,612	3,832	N/A
9/30/2019	25,951	1,030	1,595	2,836	N/A
6/30/2019	25,398	-632	1,811	3,082	N/A
3/31/2019	24,852	-654	1,259	2,592	N/A
12/31/2018	24,172	-967	1,123	2,503	N/A
9/30/2018	23,653	-727	1,425	2,899	N/A
6/30/2018	22,914	847	812	2,371	N/A
3/31/2018	22,552	676	614	2,193	N/A
12/31/2017	22,495	1,096	1,100	2,763	N/A
9/30/2017	17,061	596	1,805	3,466	N/A
6/30/2017	19,046	390	1,972	3,599	N/A
3/31/2017	20,604	701	2,208	3,839	N/A
12/31/2016	22,170	698	N/A	3,671	N/A
9/30/2016	29,650	1,203	N/A	3,372	N/A
6/30/2016	29,646	1,462	N/A	3,369	N/A
3/31/2016	29,900	1,410	N/A	3,504	N/A
12/31/2015	30,235	1,390	N/A	3,458	N/A
9/30/2015	29,303	1,429	N/A	3,366	N/A
6/30/2015	28,603	1,622	N/A	3,386	N/A
3/31/2015	27,749	1,850	N/A	3,689	N/A
12/31/2014	26,669	1,433	N/A	3,473	N/A
9/30/2014	25,843	1,672	N/A	3,491	N/A
6/30/2014	25,468	1,718	N/A	3,674	N/A
3/31/2014	25,157	1,776	N/A	3,616	N/A
12/31/2013	25,287	2,285	N/A	3,544	N/A
9/30/2013	25,345	2,105	N/A	3,593	N/A
6/30/2013	25,070	2,210	N/A	3,390	N/A
3/31/2013	24,666	2,283	N/A	3,331	N/A
12/31/2012	24,248	2,521	N/A	3,687	N/A
9/30/2012	23,787	2,584	N/A	3,650	N/A
6/30/2012	23,078	2,577	N/A	3,624	N/A

アナリストによる今後の成長予測

収入対貯蓄率: GETIB Nの予測収益成長率 (年間10.7% ) は貯蓄率 ( 7.6% ) を上回っています。

収益対市場: GETIB Nの収益 ( 10.7% ) はMX市場 ( 11.6% ) よりも速いペースで成長すると予測されています。

高成長収益: GETIB Nの収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: GETIB Nの収益 ( 4.4% ) MX市場 ( 7% ) よりも低い成長が予測されています。

高い収益成長: GETIB Nの収益 ( 4.4% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: GETIB Nの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Getinge 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Getinge AB (Publ) Provides Sales Guidance for the Year 2024

Getinge Provides Financial Guidance for the First Half, Second Half and Full Year of 2023

Getinge AB (publ) Provides Sales Guidance for the Full Year 2022

Getinge Revises Net Sales Guidance for the Full Year 2022

Recent updates

Getinge AB (publ) Declares A Dividend, Payable on 29 April 2024

Getinge AB (publ) to Report Fiscal Year 2024 Results on Jan 28, 2025

Getinge AB (publ) to Report Fiscal Year 2023 Final Results on Mar 27, 2024

Getinge AB (Publ) Proposes Dividend, Payable on April 29, 2024

Getinge Takes A Leap Forward in Cardiovascular Surgery with the 510(k) Clearance for Vasoview Hemopro 3

Getinge AB (Publ) Provides Sales Guidance for the Year 2024

Getinge Announces CFO Changes

Getinge AB (publ) (OM:GETI B) acquired Healthmark Industries Company, Inc. for $320 million.

Getinge AB (Publ) Announces Resignation of Jeanette Hedén Carlsson as Executive Vice President Brand & Communication, Effective December 31, 2023

Getinge Receives US FDA 510(K) Clearance for Servo-Air® Lite

Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire High Purity New England Inc. for approximately $290 million.

Getinge Provides Financial Guidance for the First Half, Second Half and Full Year of 2023

Full year 2022 earnings released: EPS: kr9.15 (vs kr10.90 in FY 2021)

Getinge AB (Publ) Proposes Dividend

U.S. Food and Drug Administration Broadens the Consent Decree with Getinge and Includes Its Subsidiary Datascope

Third quarter 2022 earnings released: EPS: kr2.93 (vs kr2.78 in 3Q 2021)

Getinge AB (publ) Provides Sales Guidance for the Full Year 2022

Getinge AB (Publ) Announces Executive Changes

Getinge AB (Publ) Appoints Joanna Engelke as New Executive Vice President Quality Compliance, Regulatory & Medical Affairs and Member of the Getinge Executive Team

Getinge AB (Publ) Announces Medical Device Field Action of Hls Set Advanced Products

Second quarter 2022 earnings released: EPS: kr2.21 (vs kr2.93 in 2Q 2021)

Getinge Appoints Agneta Palmér as Executive Vice President Operational Services Member of the Getinge Executive Team

Getinge AB (publ) to Report Q2, 2022 Results on Jul 19, 2022

Lena Hagman to Leave Getinge AB (publ) as Executive Vice President Quality Compliance, Regulatory & Medical Affairs

Getinge Revises Net Sales Guidance for the Full Year 2022

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘